By Business & Finance 
Johnson & Johnson is an American multinational with offices in Tallaght, Ireland. It focuses on preventing and curing diseases, developing innovative medicines, and operates 64 manufacturing facilities worldwide.
By Héloïse Chaudot
The American firm Johnson & Johnson MedTech has announced the expansion of its Research, Development and Innovation (RD&I) activities in Galway. Specifically, the company’s new offices will focus on liquid embolic procedural capabilities and stroke treatments.
Michael Gilvarry, Head of R&D for J&J MedTech Neurovascular and General Manager of the Galway site, said, “By expanding our remit from ischemic stroke to include chronic subdural hematoma, and other neurovascular conditions, our talented workforce in Galway is applying their scientific knowledge and engineering skills in new ways to find solutions to these life-threatening conditions.”
Since establishing its Galway site in 2017, the company has steadily expanded its operations. It has strengthened engineering, research, development, innovation, and manufacturing. This expansion aims to accelerate the development of therapies for acute ischemic and hemorrhagic stroke. These remain the two leading causes of death and long-term disability worldwide. At the same time, the company seeks to bring innovative treatments to patients faster.
Commenting on the expansion, Michael Lohan, CEO of IDA Ireland siad. “The work at the Galway site, which is closely aligned to our new strategy, Adapt Intelligently, will not only create high-skilled opportunities for local talent but will also help shape the future of stroke care through cutting-edge innovation developed here in the west of Ireland.”
Minister for Education and Youth of Ireland, Hildegarde Naughton TD, further added, “This Johnson & Johnson Neurovascular R&D centre underscores Ireland’s status as a global leader in medical technologies. This investment further strengthens our reputation for research excellence. The expanded facility will be pivotal in advancing stroke treatment innovation. I wish Johnson & Johnson continued success.”
Read more FDI:
